The Committee for Medicinal Products for Human Use (CHMP) said it recommended refusing Mirati’s marketing application for Krazati (adagrasib) as a treatment for non-small cell lung cancer (NSCLC ...
Amgen has its first direct competition in the KRAS inhibitor class following FDA approval of Mirati's adagrasib as Krazati for a form of lung cancer. Krazati has been cleared as a treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback